Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of MK-0736 added to ACE inhibitor or angiotensin receptor blocker therapy in adults with diabetes and hypertension
2008-004831-39Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-0736 in hypertension (HTN) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoints: Mean trough sitting systolic blood pressure and Mean trough sitting diastolic blood pressure. Started Oct 2008; status: terminated.
02
Drugs
MK-0736
03
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-004831-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004831-39.